UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Leukemia, 2015-05, Vol.29 (5), p.1123-1132

2015

Volltextzugriff (PDF)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Leukemia, 2017-11, Vol.31 (11), p.2398-2406

2017

Volltextzugriff (PDF)

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Leukemia, 2017-04, Vol.31 (4), p.829-836

2017

Volltextzugriff (PDF)

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Leukemia, 2012-11, Vol.26 (11), p.2353-2359

2012

Volltextzugriff (PDF)

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

European journal of cancer (1990), 2017-11, Vol.86, p.233-239

2017

Volltextzugriff (PDF)

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Leukemia, 2015-06, Vol.29 (6), p.1331-1335

2015

Volltextzugriff (PDF)

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Bone marrow transplantation (Basingstoke), 2013-03, Vol.48 (3), p.403-407

2013

Volltextzugriff (PDF)

Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia

Leukemia, 2006-03, Vol.20 (3), p.437-443

2006

Volltextzugriff (PDF)

Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option

Deutsche medizinische Wochenschrift (1946), 2010-09, Vol.135 (38), p.1852

2010

Volltextzugriff (PDF)

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

Diabetes care, 2012-07, Vol.35 (7), p.1446-1454

2012

Volltextzugriff (PDF)

Peer-provided psychological intervention for Syrian refugees: results of a randomised controlled trial on the effectiveness of Problem Management Plus

BMJ mental health, 2023-02, Vol.26 (1), p.e300637

2023

Volltextzugriff (PDF)

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

Leukemia, 2008-07, Vol.22 (7), p.1377-1386

2008

Volltextzugriff (PDF)

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Blood, 2003-01, Vol.101 (1), p.259-264

2003

Volltextzugriff (PDF)

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens

Biology of blood and marrow transplantation, 2018-02, Vol.24 (2), p.276-281

2018

Volltextzugriff (PDF)

Evaluation of various screening and surveillance methods in colorectal carcinoma

Schweizerische medizinische Wochenschrift, 1998-06, Vol.128 (25), p.999

1998

Volltextzugriff (PDF)

Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow

Scandinavian journal of clinical and laboratory investigation, 1998, Vol.58 (2), p.109-117

1998

Volltextzugriff (PDF)

Screening accuracy of a 14-day smartphone ambulatory assessment of depression symptoms and mood dynamics in a general population sample: Comparison with the PHQ-9 depression screening

PloS one, 2021-01, Vol.16 (1), p.e0244955-e0244955

2021

Volltextzugriff (PDF)

Short-Term Postpartum Blood Pressure Self-Management and Long-Term Blood Pressure Control: A Randomized Controlled Trial

Hypertension (Dallas, Tex. 1979), 2021-08, Vol.78 (2), p.469-479

2021

Volltextzugriff (PDF)

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The lancet oncology, 2015-12, Vol.16 (16), p.1691-1699

2015

Volltextzugriff (PDF)

Symptoms of anxiety and depression during the COVID-19 pandemic in six European countries and Australia – Differences by prior mental disorders and migration status

Journal of affective disorders, 2022-08, Vol.311, p.214-223

2022

Volltextzugriff (PDF)

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

Blood, 2012-01, Vol.119 (2), p.530-539

2012

Volltextzugriff (PDF)

Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

Blood, 2009-06, Vol.113 (26), p.6567-6571

2009

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(137)

Sprache

Englisch
(129)
Deutsch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(134)
Male
(122)
Science & Technology
(115)
Life Sciences & Biomedicine
(112)
Middle Aged
(98)
Adult
(81)
Aged
(77)
Biological And Medical Sciences
(37)
Medical Sciences
(37)
Radiology, Nuclear Medicine & Medical Imaging
(33)
Adolescent
(29)
Young Adult
(27)
Hematology
(25)
Oncology
(25)
Treatment Outcome
(25)
Medicine
(19)
Medicine & Public Health
(19)
Sensitivity And Specificity
(19)
Aged, 80 And Over
(18)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

Peer-provided psychological intervention for Syrian refugees: results of a randomised controlled trial on the effectiveness of Problem Management Plus

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens

Evaluation of various screening and surveillance methods in colorectal carcinoma

Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow

Screening accuracy of a 14-day smartphone ambulatory assessment of depression symptoms and mood dynamics in a general population sample: Comparison with the PHQ-9 depression screening

Short-Term Postpartum Blood Pressure Self-Management and Long-Term Blood Pressure Control: A Randomized Controlled Trial

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Symptoms of anxiety and depression during the COVID-19 pandemic in six European countries and Australia – Differences by prior mental disorders and migration status

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

Aktive Filter

Suchergebnisse filtern